Novo Nordisk: exclusive licence for genetic disease program
(CercleFinance.com) - Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny's sickle cell disease (SCD) gene control therapy, a move that will enable the Danish drugmaker to enter into a new therapeutic area.
Under the terms of the deal, EpiDestiny is eligible to receive over 400 million dollars in upfront, development and sales milestone payments and will receive royalties on sales.
Novo Nordisk will collaborate to develop EpiDestiny's EPI01, although EpiDestiny will retain all rights to continue development in oncology.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the deal, EpiDestiny is eligible to receive over 400 million dollars in upfront, development and sales milestone payments and will receive royalties on sales.
Novo Nordisk will collaborate to develop EpiDestiny's EPI01, although EpiDestiny will retain all rights to continue development in oncology.
Copyright (c) 2018 CercleFinance.com. All rights reserved.